Full Breakdown
Sun Pharma to Acquire Organon in $11.75 B All-Cash Deal
4/27/2026, 8:24:36 PM
Deal Announcement
Sun Pharmaceutical Industries announced an all-cash acquisition of Organon & Co. for $14 per share, valuing the New Jersey-based company at $11.75 billion (debt included). The deal, pending antitrust clearance and Organon shareholder approval, is slated to close in early 2027.
Background & Context
Organon, spun off from Merck in 2021, focuses on women’s health, biosimilars and general medicines, offering 70+ products in 140 countries with six manufacturing sites. Sun Pharma, India’s largest generics maker, added Checkpoint Therapeutics (2025) to grow its innovative-medicine business.
Key Figures & Groups
Sun Pharma is led by Executive Chairman Dilip Shanghvi and Managing Director Kirti Ganorkar; Organon is headed by Executive Chair Carrie Cox.
Timeline
- 2021 – Organon spun out of Merck.
- 27 April 2026 – Deal announced.
- Early 2027 – Expected closing.
Data & Statistics
The deal pays $14 per share, a 24 % premium to Organon’s last close. Organon posted 2025 revenue $6.2 billion, adjusted EBITDA $1.9 billion, debt $8.6 billion and cash $574 million. Sun Pharma’s 2025 revenue was $6.0 billion; combined pro-forma revenue will be $12.4 billion, with innovative-medicine sales rising to 27 % of total and net-debt/EBITDA projected at 2.3×.
Why It Matters
The deal lifts Sun Pharma into the top 25 global drugmakers, makes it a top-three women’s-health player and the seventh-largest biosimilar producer, and expands its footprint to 150 countries, diversifying revenue beyond low-margin generics.
Official Statements & Responses
Sun Pharma said the acquisition fits its innovative-medicine strategy and will create a stronger, diversified platform. Organon’s board called the all-cash deal compelling and immediately valuable for shareholders. Sun’s managing director called it a logical next step toward becoming a partner of choice for new product launches.
Criticism & Opposition
Evercore ISI analyst Umer Raffat warned Organon’s heavy debt, loss of Nexplanon exclusivity and a recent $1.2 billion acquisition raise integration risks. Observers also flag the post-deal net-debt/EBITDA of 2.3× as a leverage concern for Sun Pharma.
Conflicting Reports & Gaps
Most sources list the deal at $11.75 billion; a few cite $11.8 billion and early rumors mentioned $13 billion. Premium estimates range from a 24 % premium to the last close to >100 % relative to early-April prices. Integration timelines and expected synergies remain undisclosed.
Verbatim Quotes
- “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives.” — Dilip Shanghvi, Executive Chairman, Sun Pharma
- “Organon’s portfolio, capabilities and global reach are highly complementary to our own.” — Dilip Shanghvi, Executive Chairman, Sun Pharma
- “This transaction is a logical next step in strengthening Sun Pharma’s global business.” — Kirti Ganorkar, Managing Director, Sun Pharma
- “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders,” — Carrie Cox, Executive Chair, Organon
What’s Next
Regulatory clearances in the United States, European Union and India, plus Organon shareholder approval, are required before the early-2027 closing. Post-closing, integration teams will prioritize business continuity, talent retention and the realization of projected revenue synergies.
